SCHEMBL43811

SCHEMBL43811

N#Cc1cccc(CC(N)C(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.59
SLC7A5 Q01650 8/20 0.59
PTGS1 P23219 2/20 0.59
ALPI P09923 1/20 0.59
PKM P14618 1/20 0.59
XIAP P98170 1/20 0.59
GRIA2 P42262 1/20 0.56
DPP4 P27487 2/20 0.56
DPP7 Q9UHL4 2/20 0.56
FAP Q12884 1/20 0.56
DPP8 Q6V1X1 1/20 0.56
DPP9 Q86TI2 1/20 0.56
NOS3 P29474 2/20 0.55
NOS1 P29475 2/20 0.55
NOS2 P35228 2/20 0.55
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
EGFR P00533 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29557415 1.00 FOLH1 (0.59) FOLH1SLC7A5PTGS1ALPIPKM
SCHEMBL838038 1.00 FOLH1 (0.59) FOLH1SLC7A5PTGS1ALPIPKM
SCHEMBL29397955 1.00 FOLH1 (0.59) FOLH1SLC7A5PTGS1ALPIPKM
SCHEMBL43812 1.00 FOLH1 (0.59) FOLH1SLC7A5PTGS1ALPIPKM
Ammonia Solution, Strong SCHEMBL3564413 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM
Hydrochloric Acid SCHEMBL7591933 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM
Ammonia Solution, Strong SCHEMBL3564410 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM
Ammonia Solution, Strong SCHEMBL3564412 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM
Hydrochloric Acid SCHEMBL7042048 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM
Hydrochloric Acid SCHEMBL27695050 0.98 FOLH1 (0.58) FOLH1SLC7A5PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619043-A1 FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF Perspective Therapeutics, Inc. (US) 2025-09-24 EP claimed
WO-2025128149-A1 FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF VIEWPOINT MOLECULAR TARGETING, INC. (US) 2025-06-19 WO claimed
US-20250186630-A1 FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES VIEWPOINT MOLECULAR TARGETING, INC. (US) 2025-06-12 US claimed
US-12084476-B2 Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors Universität Duisburg-Essen (DE) 2024-09-10 US claimed
CN-113481228-B Microbial unnatural amino acid introducing system and construction method 中国药科大学 2024-07-19 CN claimed
EP-3625243-B1 TAILORED CYCLODEPSIPEPTIDES AS POTENT NON-COVALENT SERINE PROTEASE INHIBITORS UNIV DUISBURG ESSEN (DE) 2023-10-18 EP claimed
WO-2023042201-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-03-23 WO claimed
CN-111118048-B Use of chimeric phenylalanyl-tRNA synthetases/tRNAs 浙江大学 2022-06-10 CN claimed
US-20220002348-A1 TAILORED CYCLODEPSIPEPTIDES AS POTENT NON-COVALENT SERINE PROTEASE INHIBITORS Universität Duisburg-Essen (DE) 2022-01-06 US claimed
CN-113481228-A Microorganism unnatural amino acid introduction system and construction method 中国药科大学 2021-10-08 CN claimed
US-20080039626-A1 Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid WILEX AG (DE) 2008-02-14 US claimed
US-7247724-B2 Method for the production of phenylalanine derivatives WILEX AG (DE) 2007-07-24 US claimed
EP-1799665-A1 METHOD FOR CLEANING 3-HYDROXYAMIDINOPHENYLALANINE DERIVATIVES BY THE PRECIPITATION AND RECRYSTALLISATION OF A SALT AND AN AROMATIC SULPHONIC ACID Wilex AG (DE) 2007-06-27 EP claimed
WO-2006042678-A1 METHOD FOR CLEANING 3-HYDROXYAMIDINOPHENYLALANINE DERIVATIVES BY THE PRECIPITATION AND RECRYSTALLISATION OF A SALT AND AN AROMATIC SULPHONIC ACID WILEX AG (DE) 2006-04-27 WO claimed
WO-2005122379-A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY UNIV CALIFORNIA (US) 2006-03-09 WO claimed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 US claimed
WO-2005122379-A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-22 WO claimed
US-20050245757-A1 Method for the production of phenylalanine derivatives WILEX AG (DE) 2005-11-03 US claimed
EP-1525195-A2 METHOD FOR THE PRODUCTION OF PHENYLALANINE DERIVATIVES Wilex AG (DE) 2005-04-27 EP claimed
WO-2004011449-A2 METHOD FOR THE PRODUCTION OF PHENYLALANINE DERIVATIVES WILEX AG (DE) 2004-02-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy ITGA4, ITGB4, ITGA1 FOLH1 1163/4885SLC7A5 576/4885PTGS1 3492/4885
US-12084476-B2 Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors HTRA1, LNPEP, ENPEP FOLH1 270/4885SLC7A5 1601/4885PTGS1 552/4885
US-20250186630-A1 FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES FAP, FIBP, TPX2 FOLH1 177/4885SLC7A5 938/4885PTGS1 3788/4885
US-20220002348-A1 TAILORED CYCLODEPSIPEPTIDES AS POTENT NON-COVALENT SERINE PROTEASE INHIBITORS HTRA1, LNPEP, ENPEP FOLH1 270/4885SLC7A5 1601/4885PTGS1 552/4885
US-20050245757-A1 Method for the production of phenylalanine derivatives PAH, NPEPPS, DNPEP FOLH1 195/4885SLC7A5 260/4885PTGS1 2513/4885
US-20080039626-A1 Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid PEPD, PAH, PRSS3 FOLH1 166/4885SLC7A5 618/4885PTGS1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.